NCT06321536View on ClinicalTrials.gov

Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 13, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Multi-Drug Resistant Organism Colonization
Interventions
DRUG

Allogeneic Microbiota in Glycerol (9%) (AMG)

Participants will receive an Emory-manufactured MT product, delivered as 250mL via rectal enema or 30mL instillation via an existing functioning feeding tube with the rate adjusted to participant tolerance. Participants will receive three doses over the first seven days of the study.

Trial Locations (1)

30322

RECRUITING

Emory University Hospital, Atlanta

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

lead

Emory University

OTHER